Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer

Journal of Urology

Volumn 164, Issue 5, 2000, Pages 1825-1829

  McNeel, Douglas G ^b   Nguyen, Lan D ^b   Storer, Barry E ^b   Vessella, Robert ^b   Lange, Paul H ^b   Disis, Mary L ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Antibodies; Immunity; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; TUMOR ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR IMMUNITY;

EID: 0033785840     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67114-5     Document Type: Article

References (28)

1. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
2. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
3. Immunization with dendritic cells pulsed with xenogeneic prostatic acid phosphatase (PAP) administered via different routes induces cellular immune responses in prostate cancer patients
4. Immunosuppression of cell- and serum-medicated tumour-associated immunity in prostatic cancer by human seminal plasma
5. Occult carcinoma of the prostate: An oversight of immune surveillance - A working hypothesis
6. Immunobiology of carcinoma of the prostate
7. The immune response to prostate cancer: An evaluation and a review
8. Molecular characterization of defective antigen processing in human prostate cancer
9. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
10. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3
11. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
12. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
13. Circulating antibody to prostate antigen in patients with prostatic cancer
14. Generation of human cytolytic T lymphocyte lines directed against prostatespecific antigen (PSA) employing a PSA oligoepitope peptide
15. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells
16. Induction of prostate tumor-specific CDS+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide
17. Serum p53 autoantibodies: Incidence in familial breast cancer
18. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
19. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival
20. Human neoplasms elicit multiple specific immune responses in the autologous host
21. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer
22. Serum p53 antibodies as early markers of lung cancer
23. p53 autoantibodies in patients with urological tumours
24. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma
25. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory
26. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization; implications for immunotherapy of prostate cancer
27. T cell immunity specific for prostatic acid phosphatase (PAP) results in a destructive prostatitis in a rodent model
28. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen